Skip to main content

Table 1 Final selected epitopes from SARS-CoV-2 structural proteins used to design the multi-epitope-based subunit vaccine (MESV) construct

From: Reverse vaccinology assisted designing of multiepitope-based subunit vaccine against SARS-CoV-2

Sr.No Epitope Protein Position HLA alleles Antigenicity Immunogenicity
MHC class-I
1 VRFPNITNLCPF S 327–338 HLA-B*35:01 1.2 0.11
2 YRINWITGGIAI M 71–82 HLA-B*27:05 1.2 0.61
3 SFRLFARTRSMW M 99–110 HLA-B*57:01 0.6 0.05
MHC class-II
1 LLFLAFVVFLLVTLA E 18–32 HLA-DRB1*04:04 0.8 0.41
2 AFVVFLLVTLAILTA E 22–36 HLA-DRB1*04:01 0.6 0.39
3 FVVFLLVTLAILTAL E 23–37 HLA-DRB1*04:01 0.5 0.38
4 VTLACFVLAAVYRIN M 60–74 HLA-DRB1*04:08 1.0 0.36
5 ASFRLFARTRSMWSF M 98–112 HLA-DRB1*04:01 0.7 0.13
6 FRLFARTRSMWSFNP M 100–114 HLA-DRB1*04:01 0.8 0.11
B-Cell
1 SPTKLNDLCFTNVY S 383 1.6 0.67
2 EILDITPCSFGGVS S 583 1.6 0.81
3 ILPVSMTKTSVDCT S 726 1.6 0.89
4 LEQWNLVIGFLFLT M 17 0.9 0.67